Drugs / MCY-M11
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03608618 | Aug 2018 → Feb 2021 | fallopian tube adenocarcinoma, ovarian adenocarcinoma, peritoneal mesothelioma, primary peritoneal carcinoma | MaxCyte, Inc. | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MCY-M11 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03608618 ↗ |
| Modality | Cell therapy | “Mesothelin-targeting CAR” NCT03608618 ↗ |
| Route | Other | “Intraperitoneal administration” NCT03608618 ↗ |
| Target | MSLN | “Mesothelin-targeting CAR” NCT03608618 ↗ |